You have 9 free searches left this month | for more free features.

olaparib

Showing 26 - 50 of 385

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Prostate Cancer Trial in Lexington (biological, drug, radiation)

Not yet recruiting
  • Prostate Cancer
  • Pembrolizumab
  • +3 more
  • Lexington, Kentucky
    University of Kentucky
Oct 3, 2022

Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine Tumors Trial run by the National Cancer Institute (NCI)

Recruiting
  • Gastroenteropancreatico Tumors
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 19, 2023

ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a

Recruiting
  • ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer
  • a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
  • Montpellier, France
  • +1 more
Nov 16, 2022

EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine Trial run by the National Cancer Institute (NCI)

Recruiting
  • EGFR-Mutated Non-Small-Cell Lung Carcinoma
  • Small Cell/Neuroendocrine
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (Olaparib)

Recruiting
  • Castration-Resistant Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Olaparib
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Aug 23, 2022

Breast Cancer Trial in Spain (Olaparib)

Terminated
  • Breast Cancer
  • Olaparib
  • Barcelona, Spain
  • +7 more
Jan 18, 2023

Chronic Lymphocytic Leukemia Trial in Salt Lake City (RP-3500 in combination with Olaparib)

Recruiting
  • Chronic Lymphocytic Leukemia
  • RP-3500 in combination with Olaparib
  • Salt Lake City, Utah
    Huntsman Cancer Institute at the University of Utah
Sep 23, 2022

Recurrent Metastatic Melanoma, Cutaneous Melanoma, Mucosal Melanoma Trial in Boston (Olaparib)

Not yet recruiting
  • Recurrent Metastatic Melanoma
  • +3 more
  • Olaparib
  • Boston, Massachusetts
  • +1 more
Jul 29, 2022

Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8 Trial in New York

Recruiting
  • Locally Advanced Leiomyosarcoma
  • +5 more
  • Olaparib
  • +3 more
  • New York, New York
    Columbia University/Herbert Irving Cancer Center
Jan 4, 2023

Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in Boston, Houston

Recruiting
  • Recurrent Fallopian Tube Carcinoma
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 12, 2023

First-line Olaparib Combined With Bevacizumab Maintenance

Not yet recruiting
  • Ovarian Neoplasms
  • olaparib plus bevacizumab maintenance therapy
  • (no location specified)
Jun 29, 2022

Ovarian Cancer Trial in Birmingham (Carboplatin, olaparibp, embro)

Not yet recruiting
  • Ovarian Cancer
  • Birmingham, Alabama
    O'Neal Comprehensive Cancer Center at UAB
Jul 18, 2023

Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (biological, drug, other)

Recruiting
  • Biochemically Recurrent Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Durvalumab
  • +3 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Jan 26, 2023

Laryngeal Cancer Stage II, Laryngeal Cancer Stage III, Carcinoma, Squamous Cell Trial in Amsterdam (radiotherapy, Olaparib)

Active, not recruiting
  • Laryngeal Cancer Stage II
  • +3 more
  • radiotherapy
  • Olaparib
  • Amsterdam, Netherlands
    The Netherlands Cancer Institute
Sep 27, 2022

Lung Cancer Trial in Korea, Republic of (Olaparib+Bevacizumab to SCLC patients)

Recruiting
  • Lung Cancer
  • Olaparib+Bevacizumab to SCLC patients
  • Seoul, Gangnam-gu, Korea, Republic of
  • +3 more
Nov 9, 2022

Squamous Cell Carcinoma of Head and Neck Trial in Chapel Hill, Charleston (biological, drug, radiation)

Recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • Pembrolizumab
  • +3 more
  • Chapel Hill, North Carolina
  • +1 more
Oct 25, 2022

Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor Trial (procedure, biological,

Not yet recruiting
  • Advanced Malignant Solid Neoplasm
  • +2 more
  • Biopsy
  • +5 more
  • (no location specified)
Apr 8, 2023

Head Neck Cancer Trial in London, Wales (Olaparib, Cisplatin, IMRT)

Active, not recruiting
  • Head and Neck Cancer
  • Olaparib
  • +2 more
  • London, United Kingdom
  • +2 more
Nov 1, 2022

Advanced Ovarian Cancer Trial in Spain (Olaparib, Pegylated Liposomal Doxorubicin)

Completed
  • Advanced Ovarian Cancer
  • Olaparib
  • Pegylated Liposomal Doxorubicin
  • Sabadell, Barcelona, Spain
  • +7 more
Jan 25, 2023

Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma Trial in Groningen (Olaparib, Lenvatinib, Sunitinib)

Not yet recruiting
  • Renal Cell Carcinoma
  • +4 more
  • Olaparib
  • +4 more
  • Groningen, Netherlands
    University Medical Center Groningen
Jul 13, 2023

Cervical Cancer Trial in Hidaka (Pembrolizumab, Olaparib)

Active, not recruiting
  • Cervical Cancer
  • Hidaka, Saitama, Japan
    Saitama Medical Uiversity International Medical Center
Aug 8, 2022

Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Trial in Seattle (Laboratory Biomarker Analysis, Olaparib,

Active, not recruiting
  • Castration-Resistant Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Laboratory Biomarker Analysis
  • +5 more
  • Seattle, Washington
    Fred Hutch/University of Washington Cancer Consortium
Oct 19, 2022

High Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer Trial (Olaparib tablet, Navitoclax)

Recruiting
  • High Grade Serous Carcinoma
  • +2 more
  • Toronto, Ontario, Canada
  • +2 more
Nov 28, 2022

Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma

Not yet recruiting
  • Anatomic Stage III Breast Cancer AJCC v8
  • +3 more
  • (no location specified)
Jul 28, 2023

Endometrial Serous Adenocarcinoma, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor Trial in United States

Recruiting
  • Endometrial Serous Adenocarcinoma
  • +2 more
  • Biopsy
  • +3 more
  • Phoenix, Arizona
  • +3 more
Feb 2, 2023